CRNX - Crinetics Pharmaceuticals GAAP EPS of -$0.93 misses by $0.13 revenue of $0.6M beats by $0.42M
2024-05-09 16:16:26 ET
More on Crinetics Pharmaceuticals
- Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
- Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
- Crinetics Pharmaceuticals Q1 2024 Earnings Preview
- Crinetics, Syndax gain amid pitch at Sohn charity conference (update)
- Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals